Morning Briefing
Summaries of health policy coverage from major news organizations
Gilead To Boost Price Of New Hepatitis C Drug
Gilead Sciences says its next generation drug to combat hepatitis C, slated to launch next month, will be more expensive than $1,000-a-pill Sovaldi, in part because the new treatment will be shorter and simpler. Gilead also struck a deal with Indian generic drugmakers to sell lower-cost versions of Sovaldi in poor countries.
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
